ABOUT CORIOLIS PHARMA
Coriolis Pharma is a globally operating, science-driven Contract Research and Development Organization (CRDO). We provide integrated services in drug product development, analytical testing, and manufacturing support for liquid, frozen-liquid, and lyophilized drug products across all stages—from early development through commercialization and lifecycle management.
Our core expertise includes formulation development and analytical services delivered under both R&D and GMP conditions. Industry-experienced scientists design and execute platform and custom services for a broad range of biopharmaceutical modalities, including biologics, cell and gene therapies, and vaccines. We operate state-of-the-art laboratories in Martinsried, Germany and Durham, NC, USA and maintain a presence across Europe and the United States. Our services cover drug product development, analytical testing, and manufacturing support, with dedicated local project management enabling close collaboration and efficient communication throughout the project lifecycle.
FEATURED WEBINARS
-
![Formulating The Future: A Practical Guide To Nucleic Acid Therapeutics]( "Formulating The Future: A Practical Guide To Nucleic Acid Therapeutics")
Formulating The Future: A Practical Guide To Nucleic Acid TherapeuticsAn expert-led webinar exploring nucleic acid therapeutic modalities, delivery systems, formulation challenges, and real-world case studies shaping drug product development.
-
![The Road To Success]( "Drug Product Development: Preclinical To Commercial")
Drug Product Development: Preclinical To CommercialWatch a unified roadmap for drug product development, outlining phase‑appropriate studies, QTTP importance, and key requirements from preclinical stages through commercialization.
-
![Shedding Light On Surfactants Used As Excipient For Biologics]( "Understanding Surfactant Excipients In Biologic Formulations")
Understanding Surfactant Excipients In Biologic FormulationsUncover surfactant characterization, polysorbate degradation, and advanced analytics, such as multidimensional LC, to strengthen stability assessment and formulation for biologics and advanced therapies.
-
![Subvisible Particle Analysis]( "Subvisible Particle Analysis For End‑To‑End Quality")
Subvisible Particle Analysis For End‑To‑End QualitySee strategies for precise subvisible particle analysis, covering regulatory expectations, method validation, and controlling variability when transitioning workflows from R&D to GMP environments.
-
![Paving The Way To A Successful AAV Product]( "Building A Path To A Successful AAV Product")
Building A Path To A Successful AAV ProductSee state‑of‑the‑art analytical methods for AAV characterization, key quality attributes to monitor, and approaches for measuring infectivity and full‑to‑empty capsid ratios.
FEATURED ARTICLES
-
![cmo-biologics-GettyImages-1327624070]( "What To Get Right Early In Subcutaneous Biologics Development")
What To Get Right Early In Subcutaneous Biologics DevelopmentHigh-concentration biologics can face viscosity and aggregation challenges. Early modeling and targeted testing optimize formulations for stability, manufacturability, and delivery.
-
![GettyImages-1432665190-pharma-manufacturing-tubes-connectors]( "When To Conduct GMP Versus Non-GMP Stability Studies — And Why Both Matter")
When To Conduct GMP Versus Non-GMP Stability Studies — And Why Both MatterUnderstanding when to leverage GMP vs non-GMP stability studies and where each approach delivers maximum value can help sponsors make better development decisions and reach clinic faster.
-
![Pharmaceutical Laboratory-GettyImages-1419815001]( "Supporting Late-Stage Drug Product Development")
Supporting Late-Stage Drug Product DevelopmentMeet Coriolis Pharma at CPHI Worldwide in Milan to explore solutions for late-stage drug product development, manufacturing readiness, and CMC support.
-
![GettyImages-1371925389-lab-scientist-collaboration-computer-clipboard]( "Where Formulation Expertise Connects")
Where Formulation Expertise ConnectsAs pipelines grow more complex and timelines become more ambitious, companies increasingly rely on strong external partners to advance their drug products efficiently and with reduced risk.
-
![GettyImages-2187764040-cell-culture-testing-manufacturing-in-lab]( "Safeguarding Biologic Quality And Performance")
Safeguarding Biologic Quality And PerformanceA science‑driven roadmap, from QTPP to QbD and phase‑appropriate strategies, helps ensure biologics stability, manufacturability, and a smooth path to successful commercialization
CONTACT INFORMATION
Coriolis Pharma
Fraunhoferstraße 18b
Martinsried/Munich, 82152
GERMANY
Contact: https://www.coriolis-pharma.com/contact/
U.S. FACILITIES
BROCHURES
-
![GettyImages-2213157127-drug-formulation-discovery-pipette-liquid-vial]( "From Sequence To Clinic: Faster Decisions Through In Silico Insights")
In‑silico modeling enables early prediction of molecule stability, formulatability, and risks, reducing lab work, guiding candidate selection, and supporting efficient drug‑product development from sequence to clinic.
-
![GettyImages-1128195910-vial-white-powder-lyophilization]( "Advancing Lyophilization Through Formulation, Process Development")
Lyophilization development and modeling improve stability, streamline freeze‑drying cycles, reduce risks, and support efficient advancement of sensitive formulations.
-
![GettyImages-1409877704-antibody]( "Early Developability Assessment For Smarter Antibody Selection")
Integrated laboratory and in‑silico developability assessments provide early insight into antibody characteristics, reduce risks, streamline decision‑making, and accelerate progress from discovery toward successful drug product development.
-
![GettyImages-1362084368-particles]( "Beyond Detection: Advanced Strategies For Particle Root-Cause Analysis")
Utilize advanced analytical frameworks and machine learning to rapidly identify contaminants, analyze excipient degradation, and perform root cause investigations to ensure stability and compliance.
